Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Veronica Ridpath

Psychiatry Florence, SC Doctor of Osteopathy

NPI 1851825780 CMS profile 3185092

360 N Irby St, Florence, SC 29501

Open in the dashboard

General payments

$364,081

583 records reported · program years 2021–2025

Research payments

$3,300

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Veronica Ridpath of Florence, SC is reported in the CMS Open Payments database as having received $364,081 across 583 general payments and $3,300 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $253,355 303
2025 Research $3,300 1
2024 General $101,048 194
2023 General $8,984 51
2022 General $530 24
2021 General $164 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Veronica Ridpath
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Veronica Ridpath were reported at $253,355. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Veronica Ridpath Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $164 $143 $43–$576 $132
2022 $530 $153 $50–$590 $149
2023 $8,984 $170 $56–$651 $160
2024 $101,048 $179 $57–$673 $164
2025 $253,355 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axsome Therapeutics, Inc. $145,856 152 payments
  2. Neurocrine Biosciences, Inc. $71,267 101 payments
  3. ITI, Inc. $48,165 57 payments
  4. Alkermes, Inc. $44,724 79 payments
  5. Teva Pharmaceuticals USA, Inc. $29,076 58 payments
  6. AbbVie, Inc. $15,890 44 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $7,503 8 payments
  8. Janssen Pharmaceuticals, Inc $416 21 payments
  9. Otsuka America Pharmaceutical, Inc. $270 15 payments
  10. E.R. Squibb & Sons, L.L.C. $223 9 payments
  11. Other $691 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $156,240 55 payments
  2. Honoraria $90,186 32 payments
  3. Consulting Fee $80,549 45 payments
  4. Travel and Lodging $24,198 119 payments
  5. Food and Beverage $12,723 330 payments
  6. Education $185 2 payments
Products named General payments · program years 2021–2025
  1. Auvelity $145,856 152 payments
  2. INGREZZA $71,267 101 payments
  3. CAPLYTA $47,910 47 payments
  4. LYBALVI Cns $44,701 78 payments
  5. LYBALVI Cns $44,122 63 payments
  6. LYBALVI Cns $44,108 62 payments
  7. LYBALVI Cns $44,108 62 payments
  8. UZEDY $28,420 42 payments
  9. REJOYN $7,497 7 payments
  10. VRAYLAR $7,365 27 payments
  11. Other $11,050 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. AbbVie, Inc. $3,300 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

1,539

Median for Psychiatry & Neurology: 100

Drug cost

$578,900

Median for Psychiatry & Neurology: $2,986

Branded share of claims

24.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 42 $312,771
Lybalvi Olanzapine/Samidorphan Malate Brand 28 $57,355
Vraylar Cariprazine Hcl Brand 31 $44,085
Caplyta Lumateperone Tosylate Brand 22 $38,742
Rexulti Brexpiprazole Brand 11 $29,480
Auvelity Dextromethorphan Hbr/Bupropion Brand 27 $22,421
Lurasidone Hcl Generic 36 $20,013
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $17,622
Belsomra Suvorexant Brand 19 $15,751
Quetiapine Fumarate Generic 137 $2,258

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $46,542
$46,542 27 —
INGREZZA
  • Neurocrine Biosciences, Inc. $33,113
$33,113 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $11,224
$11,224 — —
VRAYLAR
  • AbbVie, Inc. $7,180
$7,180 31 —
LYBALVI
  • Alkermes, Inc. $311
$311 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

584 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record